Intermittent High-Dose Nitric Oxide Inhalation for Respiratory Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhalation therapies using gaseous nitric oxide (gNO) for treating respiratory diseases are limited by toxicity concerns at higher doses, with potential adverse effects such as methemoglobinemia and limited efficacy at approved concentrations below 80 ppm, necessitating the development of safe and effective protocols for higher dose inhalation in humans.
Innovation Solution
Intermittent inhalation of gaseous nitric oxide at concentrations of 160 ppm or more, cycled with periods of no or low concentration, monitored for safety parameters such as methemoglobin levels, end-tidal CO2, and oxygenation, to treat various respiratory conditions without significant adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher concentrations of gaseous nitric oxide (above 80 ppm) are used for treatment, then therapeutic efficacy is improved, but toxicity and adverse effects increase
Solution Approach 1:
The patent applies periodic action by implementing intermittent inhalation cycles where patients breathe gNO at high concentrations (160-480 ppm) for specific durations (e.g., 30 minutes) followed by rest periods without gNO or with lower concentrations. This periodic dosing strategy allows the therapeutic benefits of high-dose gNO to be achieved while providing intervals for the body to metabolize and eliminate excess nitric oxide, thereby preventing cumulative toxicity and adverse effects such as methemoglobinemia
Solution Approach 2:
The patent implements dynamics by making the gNO delivery system adjustable and adaptable. The concentration and duration of gNO inhalation can be dynamically modified based on individual patient response, tolerance, and clinical condition. This dynamic approach allows optimization of therapeutic efficacy while minimizing toxicity by adjusting dosing parameters in real-time based on monitored physiological parameters
2Object-affected harmful factors
If lower concentrations of gaseous nitric oxide (below 80 ppm) are used, then safety is improved, but therapeutic efficacy is limited
Solution Approach 1:
The intermittent high-low dosing regimen allows periods of high concentration inhalation (160-480 ppm) to achieve therapeutic efficacy, followed by periods of low or zero concentration to maintain safety. This periodic alternation enables the system to achieve both high efficacy during treatment phases and high safety during rest phases
Solution Approach 2:
The patent applies parameter changes by systematically varying the concentration parameter of gNO over time. The concentration is changed from low baseline levels to high therapeutic levels during inhalation cycles, and back to low levels during rest periods. This dynamic parameter modification enables the system to achieve both safety and efficacy that cannot be obtained with static low-dose therapy
3Reliability
If continuous high-dose gNO inhalation is administered, then antimicrobial and anti-inflammatory effects are enhanced, but risk of methemoglobinemia and other adverse effects increases
Solution Approach 1:
The patent implements periodic action through structured inhalation cycles that deliver high-dose gNO intermittently rather than continuously.典型方案包括30分钟吸入 followed by 3.5 hours rest, repeated multiple times daily. This periodic delivery maintains potent antimicrobial and anti-inflammatory effects during inhalation phases while preventing methemoglobinemia by allowing metabolic clearance during rest periods
Solution Approach 2:
The patent incorporates feedback mechanisms by monitoring physiological parameters such as methemoglobin levels, oxygen saturation, and respiratory function during gNO therapy. These feedback signals guide adjustments to the dosing regimen, allowing continuation of high-dose therapy when parameters are normal and triggering dose reduction or cessation when adverse effects begin to manifest
Data Source
AI summary
A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.